BRIEF published on 07/07/2025 at 15:05, 5 months 10 days ago Applied DNA Sciences se conforme aux normes de cotation du Nasdaq Biotechnologie Sciences Appliquées De L'ADN Conformité Au Nasdaq Technologies De L'ADN LineaRx
BRIEF published on 07/07/2025 at 15:05, 5 months 10 days ago Applied DNA Sciences Complies with Nasdaq Listing Standards Biotechnology Nasdaq Compliance Applied DNA Sciences DNA Technologies LineaRx
PRESS RELEASE published on 07/07/2025 at 15:00, 5 months 10 days ago Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements Applied DNA Sciences regains compliance with Nasdaq listing rule requiring minimum bid price of $1.00 per share. Company's securities to remain listed on Nasdaq Capital Market Nasdaq Compliance Applied DNA Sciences Nasdaq Capital Market Minimum Bid Price PCR-based DNA Technologies
BRIEF published on 06/17/2025 at 22:15, 6 months ago Transition de direction chez Applied DNA : le Dr Hayward, PDG, prend sa retraite Biotechnologie Changement De Direction Valeur Actionnariale ADN Appliqué Judy Murrah
BRIEF published on 06/17/2025 at 22:15, 6 months ago Leadership Transition at Applied DNA as CEO Dr. Hayward Retires Biotechnology Shareholder Value Leadership Change Applied DNA Judy Murrah
PRESS RELEASE published on 06/17/2025 at 22:10, 6 months ago Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward Judy Murrah appointed Chairperson and CEO of Applied DNA Sciences, succeeding Dr. James A. Hayward. Experienced executive aims to lead company's innovative DNA technologies CEO Appointment Applied DNA Sciences DNA Technologies Judy Murrah Dr. James A. Hayward
BRIEF published on 05/15/2025 at 22:10, 7 months 2 days ago Applied DNA Sciences enregistre une croissance modeste de ses revenus au deuxième trimestre 2025 Croissance Des Revenus Restructuration Stratégique Résultats Financiers Du Deuxième Trimestre Tendances Biopharmaceutiques Technologie De L'ADN
BRIEF published on 05/15/2025 at 22:10, 7 months 2 days ago Applied DNA Sciences Sees Modest Revenue Growth in Q2 2025 Revenue Growth Strategic Restructuring Q2 Financial Results DNA Technology Biopharma Trends
PRESS RELEASE published on 05/15/2025 at 22:05, 7 months 2 days ago Applied DNA Reports Second Quarter Fiscal 2025 Financial Results Applied DNA Sciences, Inc. (NASDAQ:APDN) reports a 44% Y/Y increase in LineaRx segment revenues contributing to a 6% total revenue growth. Strategic priorities and financial highlights for Q2 2025 disclosed Financial Results Strategic Priorities Applied DNA Sciences LineaRx Segment Therapeutic DNA Production
BRIEF published on 05/14/2025 at 17:35, 7 months 3 days ago Applied DNA Sciences publiera ses résultats financiers du deuxième trimestre et organisera une mise à jour pour les investisseurs Sciences Appliquées De L'ADN Conférence Téléphonique Pour Les Investisseurs Priorités Stratégiques Rediffusion Du Webcast Résultats Financiers Du Deuxième Trimestre 2025
Published on 12/17/2025 at 15:00, 7 hours 16 minutes ago BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/17/2025 at 14:00, 8 hours 16 minutes ago UniDoc Completes H3 Health Cube Installation in Italy
Published on 12/17/2025 at 13:35, 8 hours 41 minutes ago Silver X Mining Announces Grant of Incentive Stock Options and Restricted Share Units
Published on 12/17/2025 at 13:15, 9 hours 1 minute ago Aclara Wins UN Global Compact Award for Its Contribution to Local Employment and Suppliers
Published on 12/17/2025 at 13:00, 9 hours 16 minutes ago Gold Terra Provides a Summary of 2025 Achievements and 2026 Plan
Published on 12/17/2025 at 22:05, 11 minutes ago Abivax annonce l’acceptation de 22 abstracts sur obefazimod dans les MICI à l’ECCO 2026, dont une présentation orale sur des résultats précliniques antifibrotiques
Published on 12/17/2025 at 22:05, 11 minutes ago Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Published on 12/17/2025 at 21:22, 54 minutes ago EQS-Adhoc: DATAGROUP SE: DATAGROUP SE Management Board plans dividend of EUR 0.04 per share
Published on 12/17/2025 at 20:12, 2 hours 4 minutes ago EQS-Adhoc: Rheinmetall AG: Executive Board decides to sell activities of the civil division Power Systems – Target is sale in the first quarter of 2026; update of outlook for continuing operation
Published on 12/17/2025 at 19:39, 2 hours 37 minutes ago Avolta awarded Shanghai Pudong International Airport concession, marking a first-in-a-generation duty-free win for an international operator in mainland China
Published on 12/17/2025 at 20:39, 1 hour 37 minutes ago Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 20:39, 1 hour 37 minutes ago Aeroports de Paris SA | Tarifs des redevances aeroportuaires 2026 à Paris
Published on 12/17/2025 at 19:30, 2 hours 46 minutes ago Evolution de la composition du Conseil d’Administration
Published on 12/17/2025 at 18:00, 4 hours 16 minutes ago Outstanding Shares and Voting Rights Statement at 30 November 2025
